by Claire | Oct 23, 2022 | Uncategorized
DIADEM NAMES DR. TAMAS BARTFAI CHAIR OF ITS MEDICAL ADVISORY BOARD —Dr. Bartfai Brings Broad Academic and Pharma Industry Experience to Medical Advisory Board Comprised of Distinguished Alzheimer’s Disease Researchers and Opinion Leaders — Milan, ITALY – December 1,...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS CLINICAL DATA AND COMMERCIALIZATION PLANS FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TEST AT 2020 ALZHEIMER’S DISEASE INTERNATIONAL CONFERENCE —Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer’s Disease by Identifying Patients...
by Claire | Oct 23, 2022 | Uncategorized
NEW SCIENTIFIC PUBLICATIONS SHOW DIADEM’S BLOOD-BASED ALZOSURE® BIOMARKER TEST CAN PREDICT WHICH PATIENTS WILL PROGRESS TO ALZHEIMER’S DISEASE YEARS BEFORE SYMPTOMS OCCUR —Published Studies Explore How a Variant of p53 Contributes to the Development of Alzheimer’s...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS NEW DATA AT AAIC® SYMPOSIUM SHOWING ITS BLOOD-BASED BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE 7 YEARS BEFORE SYMPTOMS OCCUR —Analysis of 224 Longitudinal Patient Samples Confirms Diadem’s Prognostic Biomarker Can Predict...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF CLINICAL DATA SHOWING ITS ALZOSURE® BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE SIX YEARS BEFORE DIAGNOSIS —Longitudinal Data from 482 Patients Validates that AlzoSure® Can Predict Progression to AD Early in...
